Sunesis: Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS").
Read full article »
Sunesis researches, develops and commercializes oncology therapeutics for the treatment of solid and hematologic cancers.
Read more